A randomised trial evaluating the vascular endothelial growth factor inhibitor, bevacizumab (AVASTin®), as adjuvant therapy following resection of American Joint Committee on Cancer (AJCC) stage IIB (T4aN0M0), IIC (T4bN0M0) and III (TxN1-2M0) cutaneous Melanoma

Submission date	Recruitment status No longer recruiting	Prospectively registered		
03/01/2007		Protocol		
Registration date	Overall study status	Statistical analysis plan		
30/03/2007	Completed	[X] Results		
Last Edited	Condition category	[] Individual participant data		
26/10/2018	Cancer			

Plain English summary of protocol

http://www.cancerhelp.org.uk/trials/a-trial-looking-at-bevacizumab-after-surgery-for-melanoma-skin-cancer

Contact information

Type(s)

Scientific

Contact name

Dr Philippa Corrie

Contact details

Oncology Centre
Box 193
Addenbrooke's Hospital
Hills Road
Cambridge
United Kingdom
CB2 0QQ
+44 (0)1223 216083
pippa.corrie@addenbrookes.nhs.uk

Additional identifiers

EudraCT/CTIS number

2006-005505-64

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

2006-005505-64

Study information

Scientific Title

A randomised trial evaluating the vascular endothelial growth factor inhibitor, bevacizumab (AVASTin®), as adjuvant therapy following resection of American Joint Committee on Cancer (AJCC) stage IIB (T4aN0M0), IIC (T4bN0M0) and III (TxN1-2M0) cutaneous Melanoma

Acronym

AVAST-M

Study objectives

To determine the overall survival of patients treated with bevacizumab, compared with standard observation after resection of high risk melanoma.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Oxford C Multi-centre Research Ethics Committee, ref: 07/Q1606/15 - approval pending

Study design

Randomised phase III multi-centre prospective clinical trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

Health condition(s) or problem(s) studied

Cutaneous melanoma

Interventions

After resection of the high risk melanoma, patients will be given 7.5 mg per Kg bevacizumab by Intravenous (IV) infusion (30 minutes +/- 10 minutes). Bevacizumab infusions will be administered every three weeks for 51 weeks (maximum of 17 infusions) versus standard observation. The following samples will be taken/performed:

- 1. Venepuncture: blood samples will be taken at each visit, observation arm frequency equivalent to routine clinical care (n = 11), bevacizumab arm frequency higher (n = 33). The volume of blood taken on nine occasions in all will be greater, to collect blood for research purposes
- 2. Tissue/bodily sample: urinanalysis at baseline in all patients, then at intervals over ten years for patients receiving bevacizumab
- 3. Biopsy material: excision biopsy of accessible recurrent tumour tissue and adjacent normal tissue from consenting patients
- 4. Imaging Investigations with radiation: Computed Tomography (CT) (or Magnetic Resonance Imaging [MRI]) scan of head pre-randomisation
- 5. Day-case attendance: patients receiving bevacizumab will attend an appropriate clinic for drug administration
- 6. Questionnaire: quality of life questionnaire

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

Bevacizumab

Primary outcome measure

Overall survival

Secondary outcome measures

- 1. Disease-free interval
- 2. Distant metastasis-free interval
- 3. Quality of life
- 4. Safety and toxicity

Overall study start date

05/03/2007

Completion date

05/03/2017

Eligibility

Key inclusion criteria

- 1. Written informed consent
- 2. Age more than or equal to 18 years
- 3. Able to comply with the protocol
- 4. Patients with histological confirmation of completely resected American Joint Committee on Cancer (AJCC) stage IIB (T4aN0M0), IIC (T4bN0M0) and III (TxN1-2M0) cutaneous melanoma
- 5. Patients may or may not have undergone sentinel lymph node dissection and/or elective lymph node dissection
- 6. Patients must be randomised within 12 weeks of completing primary surgery (wide local excision and lymphadenectomy)
- 7. Eastern Cooperative Oncology Group (ECOG) performance status zero to one
- 8. Life expectancy more than or equal to six months
- 9. Adequate haematological function:
- a. Absolute Neutrophil Count (ANC) more than or equal to $1.5 \times 10^9/L$, and
- b. platelet count more than or equal to $100 \times 10^9/L$, and
- c. haemoglobin more than or equal to 9 g/dL (may be transfused to maintain or exceed this level) 10. Adequate liver function:
- a. total bilirubin less than 1.5 x Upper Limit of Normal (ULN), and
- b. Aspartate aminotransferase (AST), and/or Alanine aminotransferase (ALT) less than 2×10^{-5} x ULN
- 11. Adequate renal function:
- a. serum creatinine less than or equal to $1.25 \times ULN$ or calculated creatinine clearance more than or equal to 50 mL/min, and
- b. urine dipstick for proteinuria less than 2+. Patients discovered to have more than or equal to
- 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate less than or equal to 1 g of protein in 24 hours
- c. International Normalised Ratio (INR) less than or equal to 1.5 and Partial Prothrombin Time (PPT) less than or equal to 1.5 x ULN

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

1320

Key exclusion criteria

- 1. Any evidence of distant or non-regional lymph node metastases
- 2. Evidence of Central Nervous System (CNS) metastases, even if previously treated
- 3. Incomplete surgical resection of the disease
- 4. Prior chemotherapy, immunotherapy, hormonal therapy or radiotherapy for melanoma
- 5. Any surgery (including open biopsy, but excluding insertion of an indwelling catheter), or significant traumatic injury within 28 days prior to randomisation, or anticipation of the need for surgery during study treatment
- 6. Current or recent (within seven days of randomisation) use of aspirin (more than 325 mg/day)

- 7. Current or recent (within seven days of randomisation) use of full-dose oral or parenteral anticoagulants or thrombolytic agent for therapeutic purposes. Prophylactic use of anticoagulants is allowed
- 8. History or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding 9. Uncontrolled hypertension (blood pressures: systolic more than 150 mmHg and/or diastolic more than 100 mmHg)
- 10. Clinically significant (i.e. active) cardiovascular disease for example Coronary Vascular Accident (CVA) (less than or equal to six months before randomisation), myocardial infarction (less than or equal to six months before randomisation), unstable angina, congestive heart failure New York Heart Association (NYHA) class more than or equal to II, serious cardiac arrhythmia requiring medication during the study and might interfere with regularity of the study treatment, or not controlled by medication
- 11. Non-healing wound, active peptic ulcer or bone fracture
- 12. History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within six months of randomisation
- 13. Pregnant or breast-feeding females
- 14. Women with an intact uterus (unless amenorrhoeic for the last 24 months) not using, or do not agree to use, effective non-hormonal means of contraception (intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgically sterile) if randomised to the treatment arm and for a period of six months following the last administration of bevacizumab. Men who do not agree to use effective contraception if randomised to the treatment arm and for a period of 60 days following the last administration of bevacizumab
- 15. Treatment with any other investigational agent, or participation in another clinical trial within 28 days prior to randomisation
- 16. Known hypersensitivity to bevacizumab or any of its excipients
- 17. Evidence of any other disease, neurological or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment-related complications
- 18. Any condition, which, in the opinion of the investigator, might interfere with the safety of the patient or evaluation of the study objectives

Date of first enrolment 05/03/2007

Date of final enrolment 05/03/2017

Locations

Countries of recruitment England

United Kingdom

Study participating centre Addenbrooke's Hospital Cambridge

Sponsor information

Organisation

Cambridge University Hospitals NHS Foundation Trust (UK)

Sponsor details

Research and Development Department Box 146 Addenbrooke's Hospital Hills Road Cambridge England United Kingdom CB2 0QQ

Sponsor type

Hospital/treatment centre

Website

http://www.addenbrookes.org.uk/

ROR

https://ror.org/04v54gj93

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK (ref: C7535/A6408) (UK)

Alternative Name(s)

CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Plain English results	1.			No	Yes
Results article	results	01/05/2014		Yes	No
Results article	results	01/02/2018		Yes	No